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Abstract 
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inactive cortisone to active cortisol, has been 
reported to play an important role in metabolic diseases as well as chronic inflammatory diseases. The involvement 
of 11β-HSD1 in chronic periodontitis was investigated in the present study. The relationship between the levels of 
11β-HSD1, chronic periodontitis, and body mass index (BMI) was analyzed. The expression of 11β-HSD1 mRNA was 
significantly higher in the chronic periodontitis group than in the control group. Since the expression of 11β-HSD2, 
which converts active cortisol to inactive cortisone, was slightly lower in the chronic periodontitis group than in the 
controls, the ratio of 11β-HSD1 versus 11β-HSD2 was significantly higher in the chronic periodontitis group than in 
the controls. A correlation was not observed between BMI and the level of 11β-HSD1 or between BMI and the ratio of 
11β-HSD1 versus 11β-HSD2. These results suggested that an increase in the ratio of 11β-HSD1 versus 11β-HSD2 was 
associated with chronic periodontitis irrespective of obesity.
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Background
Cortisol, a major glucocorticoid hormone in humans, 
is known to have various effects on the metabolism 
of carbohydrates, fat, and proteins as well as immune 
responses: briefly, it promotes the conversion of pro-
teins and lipids into glucose, and limits and resolves the 
inflammatory process (Rhen and Cidlowski 2005; Gross 
and Cidlowski 2008). It has been reported that salivary 
cortisol levels were positively associated with the extent 
and severity of chronic periodontitis (Genco et  al.1998; 
Hilgert et  al. 2006; Ishisaka et  al. 2007; Rosania et  al. 
2009; Rai et  al. 2011; Haririan et  al. 2012; Mesa et  al. 
2014). With regard to serum cortisol levels, a report 
showed no significant differences between the chronic 
periodontitis patients and the controls (Mengel et  al. 
2002), whereas another report demonstrated that serum 
cortisol levels were significantly higher in patients with 
severe periodontitis than the controls in older Japanese 
adults who had never smoked (Ishisaka et al. 2008). Fur-
thermore, it was reported that ligature-induced experi-
mental periodontitis was more severe in Fischer 344 rats, 
which mount a strong hypothalamic–pituitary–adrenal 
(HPA) axis response leading to the increased levels of 
corticosterone (a major glucocorticoid in rodents), than 
in MHC-identical but HPA low-responding Lewis rats, 
suggesting the causal relationship between the increased 
glucocorticoid levels and severity of periodontitis (Brei-
vik et al. 2000, 2001).
Among the many enzymes involved in the biosyn-
thesis and catabolism of cortisol, 11β-hydroxysteroid 
Open Access
*Correspondence:  sawai@cc.osaka-dent.ac.jp 
5 Department of Internal Medicine, Osaka Dental University, 8-1 
Kuzuhahanazonocho, Hirakata, Osaka 573-1121, Japan
Full list of author information is available at the end of the article
Page 2 of 7Nakata et al. SpringerPlus  (2016) 5:40 
dehydrogenase (11β-HSD) catalyzes the conversion 
between active cortisol and inactive cortisone, and 
is involved in the tissue-specific intracellular regula-
tion of the actions of glucocorticoids; 11β-HSD type 1 
(11β-HSD1) converts inactive cortisone to active cor-
tisol, whereas 11β-HSD type 2 (11β-HSD2) catalyzes 
the opposite reaction (Livingstone et al. 2000; Seckl and 
Walker 2001; Tomlinson et  al. 2004; Chapman et  al. 
2013). 11β-HSD1 is known to be abundantly expressed 
in adipose tissue and the liver (Tomlinson et  al. 2004). 
The expression of 11β-HSD1 was previously reported to 
be increased in the adipocytes, especially those in vis-
ceral fat, of patients with metabolic diseases (Bujalska 
et al. 1997; Rask et al. 2001; Paulsen et al. 2007). Further-
more, transgenic mice selectively overexpressing 11β-
HSD1 in adipose tissue showed phenotypes similar to 
metabolic diseases including visceral fat obesity, insulin 
resistance, dyslipidemia, and hypertension (Masuzaki 
et al. 2001, 2003). In contrast, 11β-HSD1-deficient mice 
were protected against metabolic diseases with overnu-
trition (Kotelevtsev et  al. 1997). Moreover, inhibitors of 
11β-HSD1 have been shown to ameliorate metabolic dis-
eases and prevent atherosclerosis in mice (Hermanow-
ski-Vosatka et al. 2005; Nuotio-Antar et al. 2007). These 
findings suggest that 11β-HSD1 plays a crucial role in 
metabolic diseases, to which inhibitors of 11β-HSD1 may 
be applied as novel therapeutics. Indeed, several highly 
potent and selective 11β-HSD1 inhibitors have been 
developed for the treatment of metabolic diseases includ-
ing type 2 diabetes mellitus (Rosenstock et al. 2010; Feig 
et al. 2011; Anil et al. 2014; Okazaki et al. 2014; Hamilton 
et al. 2015).
A relationship is known to exist between meta-
bolic diseases and chronic periodontitis (Saito et  al. 
1998; Shimazaki et  al. 2007; D’Aiuto et  al. 2008; Morita 
et  al. 2010). Although the expression of 11β-HSD1 was 
recently detected in oral fibroblasts and keratinocytes 
(Cirillo et  al. 2011), the involvement of 11β-HSD1 in 
chronic periodontitis has not yet been examined. We 
recently reported preliminary results that the expres-
sion level of 11β-HSD1 in gingival tissues from patients 
with chronic periodontitis was higher than that in the 
controls (Shiraishi et  al. 2013). In the present study, we 
further investigated the expression of 11β-HSD1 as well 
as 11β-HSD2, and analyzed the relationships between the 




Periodontal tissues were obtained from patients diag-
nosed with chronic periodontitis (n  =  38), while 
those surrounding teeth extracted from patients for 
orthodontic treatments were used as controls (n =  14). 
Informed consent was obtained from all individual par-
ticipants (ages between 30 and 70 years) included in this 
study. This study was approved by the Ethics Commit-
tee at Osaka Dental University on September 16, 2009 
(approval number: 90921).
Clinical periodontal examination
Chronic periodontitis was defined as probing depth of 
>3 mm, bleeding on probing, and radiographically deter-
mined alveolar bone resorption of more than one-third 
of the root of the tooth, whereas control group patients 
did not have chronic periodontitis. The dentists who per-
formed the clinical periodontal examination were the 
members of the Department of Periodontology, Osaka 
Dental University, and therefore they used the same 
criteria for the diagnosis of chronic periodontitis. Peri-
odontal tissues, including both epitheliums and connec-
tive tissues, were surgically removed when probing depth 
after the basic periodontal treatment (including plaque 
control, scaling, and root plaining) was ≥4  mm. When 
the tooth mobility was class III in Miller classification 
and alveolar bone resorption was more than two-thirds 
of the root of the tooth at the first examination, the tooth 
was extracted without the basic periodontal treatment 
and periodontal tissues surrounding the extracted tooth 
were used for experiments.
RNA extraction
Total RNA was extracted from each sample of periodon-
tal tissue using TRIzol Reagent (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s protocol. 
Briefly, each tissue sample of 50–100  mg was homog-
enized in 1 ml of the reagent, to which 0.2 ml chloroform 
was added. After centrifugation at 12,000×g for 15  min 
at 4 °C, the aqueous phase was transferred to a new tube. 
A total of 0.5  ml isopropyl alcohol was then added and 
mixed. After centrifugation at 10,000×g for 10  min at 
4 °C, the supernatant was removed and the RNA precip-
itate was washed with 1  ml of 75  % alcohol and centri-
fuged at 7500×g for 5 min at 4 °C. After the supernatant 
was removed, the RNA pellet was air-dried and dissolved 
in RNase-free water. The quantity of RNA was calculated 
according to the absorbance at 260 nm, and the purity of 
RNA was assessed by the spectrometric absorbance ratio 
at 260 nm/280 nm.
Real‑time reverse transcription (RT)‑polymerase chain 
reaction (PCR)
RT-PCR was performed using TaqMan® RNA-to-CT™ 
1-Step Kit and StepOnePlus™ Real Time PCR System 
(Applied Biosystems, Foster City, CA, USA). TaqMan® 
Gene Expression Assays for 11β-HSD1 (#Hs01547870), 
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11β-HSD2 (#Hs00388669), receptor activator of nuclear 
factor-κB ligand (RANKL) (#Hs00243522), receptor acti-
vator of nuclear factor-κB (RANK) (#Hs00187192), oste-
oprotegerin (OPG) (#Hs00171068), and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) (#Hs02758991) 
were purchased from Applied Biosystems (Foster City, 
CA, USA). According to the manufacturer’s protocol, 1 μl 
of each probe was mixed with 0.5 μl of the RT Enzyme 
Mix, 10 μl of the RT-PCR Mix, template (100 ng RNA), 
and Nuclease-free water (total volume: 20 μl). RNA was 
reverse transcribed at 48 °C for 15 min followed by 95 °C 
for 10 min. PCR was performed up to 45 cycles at 95 °C 
for 15 s for denaturing and 60 °C for 1 min for annealing/
extension. The values of 11β-HSD1, 11β-HSD2, RANKL, 
RANK, and OPG mRNA relative to GAPDH mRNA were 
calculated in each experiment.
Body mass index (BMI)
BMI is defined as body weight (kg) divided by the square 
of body height (m).
Statistical analyses
Statistical analyses were performed using SPSS software 
version 21.0 (IBM, Armonk, NY, USA). The characteristics 
of patients with chronic periodontitis and controls were 
compared using the χ2 test for categorical variables and 
the t test for continuous variables. The Mann–Whitney U 
test was performed to compare mRNA expression levels 
between the control group and chronic periodontitis group 
or between obese and non-obese participants. Significance 
testing of Spearman’s correlation coefficient between BMI 
and the level of 11β-HSD1 or between BMI and the ratio of 
11β-HSD1 versus 11β-HSD2 was also performed.
Results
The characteristics of the study participants are summa-
rized in Table 1. No significant differences were observed 
in sex, age, height, weight, or BMI between the chronic 
periodontitis group and control group.
The expression levels of 11β-HSD1 and 11β-HSD2 
relative to GAPDH mRNA were analyzed using the real-
time RT-PCR method. The expression levels of RANKL, 
RANK, and OPG mRNA were also examined, since these 
molecules are involved in osteoclast differentiation and it 
was reported that the expression of RANKL was higher 
and that of OPG was lower in the periodontitis group 
than healthy control (Vernal et  al. 2006; Bostanci et  al. 
2007; Wara-aswapati et  al. 2007). As shown in Fig.  1, 
the values of 11β-HSD1 (Fig.  1a) and RANKL (Fig.  1c) 
were significantly (P = 0.005 and P = 0.014, respectively) 
higher in the periodontitis group than in the control 
group. Furthermore, the values of 11β-HSD2 (Fig.  1b) 
were slightly lower in the periodontitis group than in 
the control group. Thus, the ratio of 11β-HSD1 versus 
11β-HSD2 was significantly (P  =  0.001) higher in the 
periodontitis group than in the control group (Fig. 2). No 
significant differences were observed in the expression 
levels of RANK (Fig. 1d) and OPG (Fig. 1e) between the 
two groups.
Since correlations have already been reported between 
11β-HSD1 expression and metabolic diseases (Bujal-
ska et al. 1997; Rask et al. 2001; Paulsen et al. 2007) and 
between metabolic diseases and chronic periodontitis 
(Saito et  al. 1998; Shimazaki et  al. 2007; D’Aiuto et  al. 
2008; Morita et  al. 2010), the relationship between the 
expression of 11β-HSD1 in gingival tissues and BMI 
as an index of obesity was analyzed in this study. Since 
significance testing of Spearman’s correlation coefficient 
between BMI and the level of 11β-HSD1 mRNA indi-
cated P = 0.539 (Fig. 3a), and that between BMI and the 
ratio of 11β-HSD1 versus 11β-HSD2 indicated P = 0.656 
(Fig.  3b), a correlation was not observed between BMI 
and the expression of 11β-HSD1 or between BMI and 
the ratio of 11β-HSD1 versus 11β-HSD2. Furthermore, 
no significant differences were observed in the level of 
11β-HSD1 mRNA (Fig. 3c) or in the ratio of 11β-HSD1 
versus 11β-HSD2 (Fig.  3d) between obese (BMI  ≥  25, 
n =  9) and non-obese (BMI  <  25, n =  43) participants 
(P = 0.171 and P = 0.887, respectively).
Discussion
In the present study, we investigated the relationship 
between 11β-HSD1/2 and chronic periodontitis, and 
demonstrated that the expression of 11β-HSD1 as well 
as the ratio of 11β-HSD1 versus 11β-HSD2 was signifi-
cantly increased in chronic periodontitis. To the best of 
our knowledge, this is the first study to investigate the 
involvement of 11β-HSD1/2 in chronic periodontitis. 
Since it has been reported that salivary and serum cor-
tisol levels were positively associated with the extent and 
severity of periodontitis (Genco et al. 1998; Hilgert et al. 
2006; Ishisaka et  al. 2007; Rosania et  al. 2009; Rai et  al. 
Table 1 Characteristics of the study participants








No. of females/males 6/5 18/20 0.68*
Age (years) 49.1 ± 12.6 52.3 ± 11.6 0.43†
Height (cm) 163.5 ± 6.3 163.8 ± 9.6 0.91†
Weight (kg) 57.0 ± 13.0 60.4 ± 13.7 0.47†
BMI (kg/m2) 21.1 ± 3.3 22.3 ± 3.3 0.30†
Page 4 of 7Nakata et al. SpringerPlus  (2016) 5:40 
2011; Haririan et al. 2012; Mesa et al. 2014; Mengel et al. 
2002), the increased expression of 11β-HSD1 as well as 
the increased ratio of 11β-HSD1 versus 11β-HSD2 would 
result in an increase in intracellular cortisol levels, which 
might play a role in the pathophysiology of chronic 
periodontitis.
Although a correlation has already been reported 
between metabolic diseases and chronic periodontitis 
(Saito et  al. 1998; Shimazaki et  al. 2007; D’Aiuto et  al. 
2008; Morita et al. 2010), the mechanism connecting the 
diseases remains unclear. Although we demonstrated 
that the expression of 11β-HSD1 as well as the ratio of 
11β-HSD1 versus 11β-HSD2 was increased in chronic 
periodontitis, a correlation was not observed between 
BMI and the expression of 11β-HSD1 or the ratio of 
11β-HSD1 versus 11β-HSD2, suggesting that 11β-HSD1 
might play a role in chronic periodontitis irrespective of 
obesity. In accordance with these results, the involvement 
of 11β-HSD1 in other chronic inflammatory diseases 
including inflammatory bowel diseases and rheumatoid 
arthritis has been reported (Zbankova et al. 2007; Hardy 
et  al. 2008; Stegk et  al. 2009). Thus, these results may 
implicate 11β-HSD1 in the pathophysiology of chronic 
inflammation.
Since it has been known that stress is associated with 
concurrent activation of the HPA axis and that there is 
a relationship between stress and periodontitis, the rela-
tionships between stress, cortisol and periodontitis have 
been investigated in several studies (Genco et  al. 1998; 
Hilgert et  al. 2006; Rosania et  al. 2009; Rai et  al. 2011; 
Haririan et al. 2012; Mesa et al. 2014; Mengel et al. 2002). 
Since 11β-HSD1 converts inactive cortisone to active 
Fig. 1 Comparison of mRNA levels in gingival tissues between the chronic periodontitis group (P) and control group (C). Box and whisker plots of 
the values of each mRNA relative to GAPDH mRNA are shown. Outliers are omitted. a 11β-HSD1; b 11β-HSD2; c RANKL; d RANK; e OPG. *P < 0.01; 
+P < 0.05
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cortisol intracellularly, the increased expression of 11β-
HSD1 in chronic periodontitis seems to be independent 
of the HPA axis. However, further studies are required 
to determine the relationship between stress and the 
expression of 11β-HSD1 in chronic periodontitis.
The increased expression of RANKL in chronic peri-
odontitis in the present study is consistent with previ-
ous findings (Vernal et  al. 2006; Bostanci et  al. 2007; 
Wara-aswapati et  al. 2007). Although the expression of 
OPG was slightly increased in chronic periodontitis in 
the present study, it was reduced in two previous studies 
(Bostanci et  al. 2007; Wara-aswapati et  al. 2007). Thus, 
the role for OPG in chronic periodontitis remains to be 
determined.
There are limitations related to this study since it is a 
case–control study. Moreover, there are limitations of 
β error in this study due to a relatively small number of 
controls as well as obese participants.
Conclusions
We demonstrated that the increased expression of 11β-
HSD1 as well as the increased ratio of 11β-HSD1 versus 
11β-HSD2 was associated with chronic periodontitis. 
Since a correlation was not observed between body mass 
index and 11β-HSD1 expression or 11β-HSD1/2 ratio, 
the increased 11β-HSD1 expression or 11β-HSD1/2 
ratio might play a role in the pathophysiology of chronic 
periodontitis irrespective of obesity. Further investiga-
tions will be needed to elucidate the precise role of 11β-
HSD1/2 in chronic periodontitis.
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